Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastatic breast cancer

M J Kennedy1

  • 1Johns Hopkins Oncology Center, Medical Oncology, Baltimore, MD 21287-8936, USA.

Current Opinion in Oncology
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Managing metastatic breast cancer involves challenging treatments. Taxanes show promise, especially in resistant cases, and combination therapies are under investigation, with antibody and bisphosphonate therapies offering targeted benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incidence of arthrogenic muscle inhibition in acute knee injuries: a prospective cohort study in a tertiary acute knee unit.

Asia-Pacific journal of sports medicine, arthroscopy, rehabilitation and technology·2025
Same author

Simultaneous "fix and replace" has non inferior survivorship compared to staged arthroplasty in acetabular fracture management at two year follow up.

Injury·2025
Same author

CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland.

Irish journal of medical science·2025
Same author

Heterogeneous integration of a III-V quantum dot laser on high thermal conductivity silicon carbide.

Optics letters·2023
Same author

Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.

Breast cancer research and treatment·2021
Same author

Low loss (Al)GaAs on an insulator waveguide platform.

Optics letters·2019

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Treatment

Background:

  • Metastatic breast cancer presents significant management challenges.
  • Taxanes demonstrate activity in resistant disease, prompting evaluation in combination regimens.
  • Cardiac toxicity is a concern with certain combination therapies like paclitaxel and doxorubicin.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for metastatic breast cancer.
  • To evaluate the efficacy and toxicity of various treatment modalities.
  • To highlight the role of predictive factors and targeted therapies.

Main Methods:

  • Review of current literature on taxane-based therapies and combination regimens.
  • Analysis of data regarding docetaxel activity in anthracycline-resistant disease.

Related Experiment Videos

  • Examination of the role of HER-2 protein as a predictive factor and antibody therapy.

    • Main Results:

    • Paclitaxel and doxorubicin combination shows activity but carries cardiac risks.
    • Docetaxel is highly active, particularly in anthracycline-resistant metastatic breast cancer.
    • HER-2 positivity predicts response to antibody therapy; bisphosphonates aid in managing bony metastases.

    Conclusions:

    • Combination regimens, particularly with taxanes, are crucial in first-line metastatic breast cancer therapy.
    • Targeted therapies like anti-HER2 antibodies and bisphosphonates offer specific benefits for patient subgroups.
    • High-dose therapy's role remains controversial and largely confined to clinical trials.